| Price and Chart delayed at least 15 mintues. |
|
Price
$ 55.04
|
Change
0.00
|
|
Open
0.00
|
% Change
0.0%
|
|
Prev Close
55.04
|
Volume
NA
|
|
Market Value
4 bil
|
P/E Ratio
17.6
|
|
Bid
55.04
|
EPS
3.12
|
|
Ask
55.10
|
Dividend
0.00
|
|
High
0.00
|
Yield
0.0
|
|
Low
0.00
|
Shares Out
74 mil
|
|
52wk High
81.35
|
52wk Low
54.63
|
|
Industry: Drug Manufacturers - Other
|
|
Sector: Healthcare
|
CEPH Profile
An international biopharmaceutical company, engaged in the discovery, development and commercialization of innovative products in three core therapeutic areas: central nervous system pain and oncology.
Cephalon Inc
41 Moores Road
P.O. Box 4011 Frazer, PA 19355
Phone: (610) 344-0200
Fax: (610) 738-6590
Web Site: www.cephalon.com
CEPH Wires Headlines
|
|
| 07.01.09 |
|
ANALYSIS-Depressed Cephalon shares pose buying opportunity
|
|
| 06.19.09 |
|
BRIEF-Cephalon provides clinical update on Lestaurtinib
|
|
| 06.19.09 |
|
Cephalon says leukemia drug missed goal in trial
|
|
| 06.15.09 |
|
BRIEF-Cephalon says offer price for Arana raised to A$1.40 per share -filing
|
More CEPH From Wires Headlines >
Forbes.com on CEPH RSS
No news found in the past 30 days.CEPH Press Releases
|
|
| 06.30.09 |
|
Cephalon Quarterly Conference Call Invitation |
|
| 06.19.09 |
|
Cephalon Provides Clinical Update on Lestaurtinib in Relapsed Acute Myelogenous Leukemia |
|
| 06.10.09 |
|
NUVIGIL Jet Lag Disorder Data Presented at the SLEEP 2009 23rd Annual Meeting of the Associated... |
More CEPH Press Releases >
CEPH Ratios & Returns
| Price-to-sales |
1.85 |
| Return on Equity |
15.2 |
| Operating Margin |
28.3 |
| Profit Margin |
11.1% |
More CEPH Ratios & Returns >
CEPH Financials
| Sales |
$2.051303 bil |
| Profits |
$0.227479 bil |
| Assets |
$3.578166 bil |
| Employees |
2780.0 |
|
|
|
Cephalon is ranked # 1844 on the 2009 Forbes 2000 List
|
|
Thomson / IBES Earnings Estimates on CEPH
Accounting Risk
Buy/Hold/Sell Analysis
Forbes Investment Guru Commentary on CEPH
RSS News Feed on CEPH
|
A D V E R T I S E M E N T
|